La Jolla Pharmaceutical Company Clinical Trials
Sponsors / La Jolla Pharmaceutical Company
According to ClinicalTrials.gov, La Jolla Pharmaceutical Company has served as lead sponsor on 20 registered trials. 2 trials are actively recruiting participants, 0 remain active without open enrollment, and 10 have concluded. 4 of these trials ended early via termination or withdrawal. The most common reasons cited for termination include efficacy or futility findings, funding constraints. The cumulative planned enrollment figure across all listed trials is 2,766 participants. All figures are drawn directly from ClinicalTrials.gov and updated as sponsors submit revisions.
20
Total Trials
2
Recruiting
0
Other Active
10
Completed
4
Terminated / Withdrawn
2,766
Total Enrollment
Termination reasons: Efficacy50% · Funding25% · Other25%
Recent Terminations
- Beta-Thalassemia"Terminated early for lack of efficacy as determined by interim endpoint analyses"
- Hepatorenal Syndrome Type I and Type II"Corporate decision"
- Multiple Myeloma"Lack of funding"
- Lupus Erythematosus, Systemic"Interim efficacy analysis indicated it would be futile to continue study."
Active Trials (0 total)
- NCT06487585
- Liver Transplant; Complications PHASE2/PHASE3NCT04901169
Top Conditions
Catecholamine-resistant hypotension (crh) (3) Chronic kidney disease (3) Autoimmune diseases (1) Beta-thalassemia (1) Catecholamine-resistant hypotension (crh) (1) Chronic lymphocytic leukemia (1) Diabetic chronic kidney disease (1) Distributive shock (1) Hepatorenal syndrome type i and type ii (1) Hereditary hemochromatosis (1)